Definium Therapeutics Inc
definiumtx.comWhat Do They Do?
Develops experimental medicines based on psychedelic and empathogen compounds for people with anxiety, depression, autism and other brain health disorders.
10-K for FY2025, filed Feb 26, 2026We are a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is…View ↗
Our first lead product candidate, DT120 ODT, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that we are…View ↗
Our second lead product candidate, DT402 (previously referred to as MM402), also referred to as R(-)-MDMA, is our proprietary form of the…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Feb 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$159MView ↗
- ▲ +272% (Loss)
- vs −$42.7M in Q2 FY2025
Depression added to lead program
The older report described the lysergide candidate for generalized anxiety disorder and attention deficit hyperactivity disorder; the latest describes it for generalized anxiety disorder and major depressive disorder.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Feb 26, 2026Our lead product candidate, MM-120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that we are developing for…View ↗
Our first lead product candidate, DT120 ODT, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that we are…View ↗
Who Do They Compete With?
Competes with AtaiBeckley, Compass, GH Research, Helus, Johnson & Johnson, Otsuka, Intra-Cellular Therapies, Axsome, Resilient, Nova Mentis Life Science, Mycrodose Therapeutics, Novartis, Roche, Pfizer, Biogen, Jazz Pharmaceuticals, Supernus Pharmaceuticals, AbbVie, Neumora Therapeutics, and Praxis Precision Medicines
10-K for FY2025, filed Feb 26, 2026Our most advanced product candidate, DT120 ODT, is in Phase 3 development for GAD and MDD, with additional psychiatric indications under…View ↗
Loading...
